Kuros Biosciences Ltd (CSBTF)
9.05
0.00 (0.00%)
USD |
OTCM |
Apr 24, 16:00
Kuros Biosciences Total Liabilities (Quarterly): 17.56M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.56M |
| June 30, 2023 | 15.90M |
| June 30, 2023 | 15.90M |
| December 31, 2022 | 15.19M |
| June 30, 2022 | 15.79M |
| June 30, 2022 | 15.79M |
| December 31, 2021 | 15.71M |
| June 30, 2021 | 9.268M |
| June 30, 2021 | 9.268M |
| December 31, 2020 | 11.17M |
| June 30, 2020 | 9.174M |
| June 30, 2020 | 9.174M |
| December 31, 2019 | 10.32M |
| June 30, 2019 | 10.18M |
| June 30, 2019 | 10.18M |
| December 31, 2018 | 9.485M |
| June 30, 2018 | 10.29M |
| June 30, 2018 | 10.29M |
| December 31, 2017 | 13.29M |
| June 30, 2017 | 13.86M |
| June 30, 2017 | 13.86M |
| December 31, 2016 | 5.352M |
| June 30, 2016 | 5.835M |
| June 30, 2016 | 5.835M |
| Date | Value |
|---|---|
| December 31, 2015 | 5.816M |
| June 30, 2015 | 1.687M |
| June 30, 2015 | 1.687M |
| December 31, 2014 | 44.35M |
| June 30, 2014 | 42.14M |
| June 30, 2014 | 42.14M |
| December 31, 2013 | 40.87M |
| September 30, 2013 | 29.97M |
| June 30, 2013 | 24.17M |
| June 30, 2013 | 24.17M |
| March 31, 2013 | 21.91M |
| December 31, 2012 | 22.72M |
| September 30, 2012 | 23.44M |
| June 30, 2012 | 19.22M |
| March 31, 2012 | 18.24M |
| December 31, 2011 | 45.72M |
| September 30, 2011 | 53.26M |
| June 30, 2011 | 55.58M |
| March 31, 2011 | 51.30M |
| December 31, 2010 | 50.79M |
| September 30, 2010 | 47.73M |
| June 30, 2010 | 42.11M |
| March 31, 2010 | 49.74M |
| December 31, 2009 | 58.38M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
9.174M
Minimum
Jun 2020
17.56M
Maximum
Dec 2023
12.70M
Average
11.17M
Median
Dec 2020
Total Liabilities (Quarterly) Benchmarks
| AC Immune SA | 26.40M |
| CRISPR Therapeutics AG | 346.77M |
| Addex Therapeutics Ltd | 4.163M |
| NLS Pharmaceutics Ltd | 6.557M |
| Molecular Partners AG | 26.10M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 85.08M |
| Shareholders Equity (Quarterly) | 67.52M |
| Current Ratio | 2.062 |